Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-98M | $-100M | $-99M | -40.5% | - | 1.7% |
| 2024 | $0M | $-96M | $-98M | $-82M | -84.2% | - | 48.1% |
| 2023 | $0M | $-64M | $-66M | $-60M | -58.5% | -100.0% | 12.0% |
| 2022 | $1M | $-58M | $-59M | $-55M | 52.5% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0.65 | 0 | 0 | 0 |
| Operating Revenue | - | 0.65 | 0 | 0 | 0 |
| Operating Expense | - | 61.16 | 68.51 | 105.77 | 109.26 |
| Research And Development | - | 49.16 | 53.13 | 74.09 | 63.80 |
| Selling General And Administration | - | 12 | 15.38 | 31.68 | 45.46 |
| Total Expenses | - | 61.16 | 68.51 | 105.77 | 109.26 |
| Operating Income | - | -60.51 | -68.51 | -105.77 | -109.26 |
| Total Operating Income As Reported | - | -60.51 | -68.51 | -105.77 | -109.26 |
| EBITDA | - | -58.04 | -64.35 | -96.19 | -97.68 |
| Normalized EBITDA | - | -58.04 | -63.82 | -96.19 | -101.07 |
| EBIT | - | -59.19 | -66.19 | -98.20 | -99.76 |
| Interest Income | - | 1.32 | 2.87 | 7.58 | 6.13 |
| Interest Expense | - | 0.09 | 0.20 | 0.14 | 0.21 |
| Net Interest Income | - | 1.23 | 2.66 | 7.44 | 5.92 |
| Other Non Operating Income Expenses | - | 0 | -0.01 | -0.01 | -0.02 |
| Other Income Expense | - | 0 | -0.54 | -0.01 | 3.37 |
| Interest Income Non Operating | - | 1.32 | 2.87 | 7.58 | 6.13 |
| Interest Expense Non Operating | - | 0.09 | 0.20 | 0.14 | 0.21 |
| Net Non Operating Interest Income Expense | - | 1.23 | 2.66 | 7.44 | 5.92 |
| Pretax Income | - | -59.28 | -66.39 | -98.33 | -99.96 |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -59.28 | -66.39 | -98.33 | -99.96 |
| Net Income From Continuing And Discontinued Operation | - | -59.28 | -66.39 | -98.33 | -99.96 |
| Net Income From Continuing Operation Net Minority Interest | - | -59.28 | -66.39 | -98.33 | -99.96 |
| Net Income | - | -59.28 | -66.39 | -98.33 | -99.96 |
| Net Income Common Stockholders | - | -59.28 | -66.39 | -98.33 | -99.96 |
| Net Income Including Noncontrolling Interests | - | -59.28 | -66.39 | -98.33 | -99.96 |
| Normalized Income | - | -59.28 | -65.86 | -98.33 | -103.35 |
| Diluted NI Availto Com Stockholders | - | -59.28 | -66.39 | -98.33 | -99.96 |
| Basic Average Shares | 25.17 | 25.17 | 5.35 | 31.79 | - |
| Diluted Average Shares | 25.17 | 25.17 | 5.35 | 31.79 | - |
| Reconciled Depreciation | - | 1.14 | 1.84 | 2 | 2.08 |
| Total Unusual Items | 0 | - | -0.53 | - | 3.39 |
| Total Unusual Items Excluding Goodwill | 0 | - | -0.53 | - | 3.39 |
| Special Income Charges | 0 | - | - | - | - |
| Gain On Sale Of Security | - | - | -0.53 | - | 3.39 |
| General And Administrative Expense | - | 12 | 15.38 | 31.68 | 45.46 |
| Other Gand A | - | 12 | 15.38 | 31.68 | 45.46 |
| Total Other Finance Cost | -0.02 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc.this co. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| OmniAb, Inc. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Benitec Biopharma Inc. | BNTC | $380M | -10.01 | 3.90 | -39.0% | -6.83 |
| Viemed Healthcare, Inc. | VMD | $377M |
| - |
| - |
| - |
| - |
| - |
| 25.26 |
| 2.67 |
| 10.6% |
| 7.36 |
| CapsoVision, Inc. | CV | $377M | -14.88 | 28.41 | -190.9% | -14.73 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Delcath Systems, Inc. | DCTH | $372M | 137.96 | 3.35 | 2.4% | 327.03 |
| Perspective Therapeutics, Inc. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Peer Median | - | -5.77 | 2.31 | -36.4% | -5.08 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Oct has averaged the highest return (+19.1%); Feb the lowest (-21.7%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.4%Negative MonthJan 2026: -25.38% | -3.1%Negative MonthFeb 2026: -3.10% | -20.1%Negative MonthMar 2026: -20.06% | -0.8%Neutral MonthApr 2026: -0.78% | -9.7%Negative MonthMay 2026: -9.75% | -9.4%Negative MonthJun 2026: -9.44% | -11.3%Negative MonthJul 2026: -11.28% | +30.0%*Positive MonthAug 2026: +30.02% | — | — | — | — |
| 2025 | -17.5%Negative MonthJan 2025: -17.48% | -47.3%Negative MonthFeb 2025: -47.33% | +21.3%Positive MonthMar 2025: +21.33% | +13.3%Positive MonthApr 2025: +13.26% | -30.8%Negative MonthMay 2025: -30.79% | +47.8%Positive MonthJun 2025: +47.79% | +17.7%Positive MonthJul 2025: +17.66% | +1.3%Neutral MonthAug 2025: +1.27% | +38.6%Positive MonthSep 2025: +38.62% | +50.8%Positive MonthOct 2025: +50.75% | -1.5%Neutral MonthNov 2025: -1.50% | +0.7%Neutral MonthDec 2025: +0.71% |
| 2024 | +27.7%Positive MonthJan 2024: +27.72% | -14.7%Negative MonthFeb 2024: -14.70% | +7.3%Positive MonthMar 2024: +7.25% | -20.6%Negative MonthApr 2024: -20.60% | +33.6%Positive MonthMay 2024: +33.57% | -3.5%Negative MonthJun 2024: -3.55% | -21.8%Negative MonthJul 2024: -21.76% | -8.3%Negative MonthAug 2024: -8.29% | -21.5%Negative MonthSep 2024: -21.46% | -12.6%Negative MonthOct 2024: -12.61% | +4.2%Positive MonthNov 2024: +4.18% | -20.0%Negative MonthDec 2024: -20.05% |
| 2023 | — | — | — | — | — | — | — | — | — | — | — | +5.5%Positive MonthDec 2023: +5.50% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 4 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
